Burlington, Canada
Burlington, Canada
Time filter
Source Type

Americas Gold Nanoparticles Market Information by Type (nanorods, nanoshells , nanocages) by Application (photodynamic therapy, diagnostics, medical imaging), by End-users (Hospitals, Clinics,Dental clinics) - Forecast to 2027Pune, India - April 25, 2017 /MarketersMedia/ — Market Scenario The market for Gold nanoparticles is increasing rapidly due to increasing advancement in nanotechnologies. The factors that influence the growth of Gold nanoparticles market; expanding medical diagnostics industry, increasing growth in advance healthcare technology, high advantages in medicinal imaging applications and many others. Key Players • Cytodiagnostics (Canada), • Goldsol (U.S), • NanoHybrids Corp (Austin), • Nanopartz Inc (U.S), • Nanosphere (Canada), • Nanostellar (U.S), • NanoRods LLC (U.S), • Sigma Aldrich (U.S), Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1129 Segments On the basis of types • Nanorods • Nanoshells • Nanocages On the basis of application • Photodynamic therapy • Diagnostics • Medical imaging and others On the basis of End-users • Medical • Electronics • Catalysis Taste the market data and market information presented through more than 50 market data tables and figures spread in 120 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Americas Gold Nanoparticles Market Research Report - Forecast to 2027" Study Objectives of Gold nanoparticles • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Americas Gold nanoparticles market • To provide insights about factors affecting the market growth • To Analyze the Gold nanoparticles market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Rest of the World (ROW) • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by Application, by End-users and its sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The reports cover analysis Americas North America • US • Canada Latin America The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Related Reports Global Blood Transfusion Diagnostics Market Information by Type (Instruments, Reagents), By Application (Blood Grouping, disease Screening), By End users (Hospital, laboratories, Blood Banks, Plasma Fractionation Facilities) - Forecast to 2027.Know more about this report @ https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. Contact Info:Name: Akash AnandEmail: akash.anand@marketresearchfuture.comOrganization: Market Research FutureAddress: Magarpatta Road, Hadapsar,Phone: 6468459349Source URL: http://marketersmedia.com/americas-gold-nanoparticles-market-key-players-analysis-cytodiagnostics-goldsol-nanohybrids-corp-nanopartz-inc-nanosphere-nanostellar-nanorods-llc/189913For more information, please visit https://www.marketresearchfuture.comSource: MarketersMediaRelease ID: 189913

LFA (Lateral Flow Assay) market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.  The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry Players. The Players mentioned in our report  GE healthcare  Merck Millipore  Sartorius  Pall  Kestrel Bio  Abingdon Health  BioDot, Inc  IMMY  Skannex  DCN  Qiagen  Senova  Scienion  ANP Technology, Inc  BBI Solutions  Cytodiagnostics Chapter 1 About the LFA (Lateral Flow Assay) Industry      1.1 Industry Definition        1.1.1 Types of LFA (Lateral Flow Assay) industry   Pregnancy   Drugs   Swine flue   HIV   Others      1.2 Main Market Activities      1.3 Similar Industries      1.4 Industry at a Glance Chapter 2 World Market Competition Landscape      2.1 LFA (Lateral Flow Assay) Markets by Regions        2.1.1 USA  Market Revenue (M USD) by Types, Through 2021  Market Revenue (M USD) by Applications, Through 2021  Major Players Revenue (M USD) in 2015        2.1.2 Europe  Market Revenue (M USD) by Types, Through 2021  Market Revenue (M USD) by Applications, Through 2021  Major Players Revenue (M USD) in 2015        2.1.3 China  Market Revenue (M USD) by Types, Through 2021  Market Revenue (M USD) by Applications, Through 2021  Major Players Revenue (M USD) in 2015        2.1.4 India  Market Revenue (M USD) by Types, Through 2021  Market Revenue (M USD) by Applications, Through 2021  Major Players Revenue (M USD) in 2015        2.1.5 Japan  Market Revenue (M USD) by Types, Through 2021  Market Revenue (M USD) by Applications, Through 2021  Major Players Revenue (M USD) in 2015        2.1.6 South East Asia  Market Revenue (M USD) by Types, Through 2021  Market Revenue (M USD) by Applications, Through 2021  Major Players Revenue (M USD) in 2015      2.2 World LFA (Lateral Flow Assay) Market by Types  Pregnancy  Drugs  Swine flue  HIV  Others      2.3 World LFA (Lateral Flow Assay) Market by Applications      2.4 World LFA (Lateral Flow Assay) Market Analysis        2.4.1 World LFA (Lateral Flow Assay) Market Revenue and Growth Rate 2011-2016        2.4.2 World LFA (Lateral Flow Assay) Market Consumption and Growth rate 2011-2016        2.4.3 World LFA (Lateral Flow Assay) Market Price Analysis 2011-2016 Chapter 3 World LFA (Lateral Flow Assay) Market share      3.1 Major Production Market share by Players      3.2 Major Revenue (M USD) Market share by Players      3.3 Major Production Market share by Regions in 2015, Through 2021      3.4 Major Revenue (M USD) Market share By Regions in 2015, Through 2021 For more information, please visit http://www.wiseguyreports.com

Normanno N.,Cell Biology and Biotherapy Unit | Normanno N.,Crom Centro Ricerche Oncologiche Of Mercogliano | Pinto C.,S Orsola Malpighi Hospital | Taddei G.,University of Florence | And 4 more authors.
Journal of Thoracic Oncology | Year: 2013

Introduction: The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytology organized an external quality assessment (EQA) scheme for EGFR mutation testing in non-small-cell lung cancer. Methods: Ten specimens, including three small biopsies with known epidermal growth factor receptor (EGFR) mutation status, were validated in three referral laboratories and provided to 47 participating centers. The participants were requested to perform mutational analysis, using their usual method, and to submit results within a 4-week time frame. According to a predefined scoring system, two points were assigned to correct genotype and zero points to false-negative or false-positive results. The threshold to pass the EQA was set at higher than 18 of 20 points. Two rounds were preplanned. Results: All participating centers submitted the results within the time frame. Polymerase chain reaction (PCR)/sequencing was the main methodology used (n = 37 laboratories), although a few centers did use pyrosequencing (n = 8) or real-time PCR (n = 2). A significant number of analytical errors were observed (n = 20), with a high frequency of false-positive results (n = 16). The lower scores were obtained for the small biopsies. Fourteen of 47 centers (30%) that did not pass the first round, having a score less than or equal to 18 points, used PCR/sequencing, whereas 10 of 10 laboratories, using pyrosequencing or real-time PCR, passed the first round. Eight laboratories passed the second round. Overall, 41of 47 centers (87%) passed the EQA. Conclusion: The results of the EQA for EGFR testing in non-smallcell lung cancer suggest that good quality EGFR mutational analysis is performed in Italian laboratories, although differences between testing methods were observed, especially for small biopsies. Copyright ©2013 by the International Association for the Study of Lung Cancer.

Ikenberg H.,Cytomol | Bergeron C.,Laboratoire Cerba | Schmidt D.,Institute for Pathology | Griesser H.,Cytodiagnostics | And 13 more authors.
Journal of the National Cancer Institute | Year: 2013

Background: Pap cytology is known to be more specific but less sensitive than testing for human papillomavirus (HPV) for the detection of high-grade cervical intraepithelial neoplasia (CIN2+). We assessed whether p16/Ki-67 dual-stained cytology, a biomarker combination indicative of transforming HPV infections, can provide high sensitivity for CIN2+ in screening while maintaining high specificity. Results were compared with Pap cytology and HPV testing. Methods: A total of 27349 women 18 years or older attending routine cervical cancer screening were prospectively enrolled in five European countries. Pap cytology, p16/Ki-67 immunostaining, and HPV testing were performed on all women. Positive test results triggered colposcopy referral, except for women younger than 30 years with only positive HPV test results. Presence of CIN2+ on adjudicated histology was used as the reference standard. Two-sided bias-corrected McNemar P values were determined. Results: The p16/Ki-67 dual-stained cytology positivity rates were comparable with the prevalence of abnormal Pap cytology results and less than 50% of the positivity rates observed for HPV testing. In women of all ages, dual-stained cytology was more sensitive than Pap cytology (86.7% vs 68.5%; P <. 001) for detecting CIN2+, with comparable specificity (95.2% vs 95.4%; P =. 15). The relative performance of the tests was similar in both groups of women: younger than age 30 and 30 years or older. HPV testing in women 30 years or older was more sensitive than dual-stained cytology (93.3% vs 84.7%; P =. 03) but less specific (93.0% vs 96.2%; P <. 001). Conclusions: The p16/Ki-67 dual-stained cytology combines superior sensitivity and noninferior specificity over Pap cytology for detecting CIN2+. It suggests a potential role of dual-stained cytology in screening, especially in younger women where HPV testing has its limitations. © The Author 2013. Published by Oxford University Press.

Reuschenbach M.,University of Heidelberg | Clad A.,Albert Ludwigs University of Freiburg | Von Knebel Doeberitz C.,University of Heidelberg | Wentzensen N.,University of Heidelberg | And 5 more authors.
Gynecologic Oncology | Year: 2010

Objective: The prognostic value of dysplastic lesions of the uterine cervix cannot be adequately determined by Pap cytology alone. Detection of HPV DNA increases the diagnostic sensitivity. However, due to the very high prevalence of transient HPV infections, HPV DNA testing suffers from poor diagnostic specificity. Biomarkers that highlight the shift from self limited transient to potentially dangerous transforming HPV infections may improve the accuracy of cervical cancer screening. We evaluated HPV E6/E7 mRNA detection (APTIMA), p16INK4a-immunocytology (CINtec), and HPV DNA testing (HC2) to identify women with high grade cervical neoplasia in a disease-enriched cross-sectional cohort. Methods: Liquid based cytology specimens were collected from 275 patients. All assays were performed from these vials. Detection rates of each test were evaluated against conventional H&E based histopathology alone and stratified by p16INK4a-immunohistochemistry (IHC). Results: All assays yielded a high sensitivity for the detection of CIN3+ (96.4% (95% CI, 90.4-98.8) for HC2, 95.5% (89.2-98.3) for APTIMA and CINtec) and CIN2+ (91.5% (85.8-95.1) for HC2, 88.4% (82.3-92.7) for APTIMA, 86.6% (80.2-91.2) for CINtec). The specificity to detect high grade dysplasia was highest for CINtec p16INK4a-cytology (60.6% (52.7-68.0) in CIN3+ and 74.8% (65.5-82.3) in CIN2+), followed by APTIMA (56.4% (48.4-64.0) in CIN3+ and 71.2% (61.7-79.2) in CIN2+) and HC2 (49.1% (41.3-56.9) in CIN3+ and 63.4% (53.7-72.1) in CIN2+). All tests had higher sensitivity using p16INK4a-IHC-positive CIN2+ lesions as endpoint. Conclusions: Biomarkers that detect HPV induced dysplastic changes in the transforming stage are promising tools to overcome the current limitations of cervical cancer screening. © 2010 Elsevier Inc.

Vral A.,Ghent University | Magri V.,Urology Secondary Care Clinic | Montanari E.,University of Milan | Gazzano G.,Cytodiagnostics | And 3 more authors.
International Journal of Oncology | Year: 2012

Inflammatory processes are important components in the pathogenesis of many human cancers. According to the 'injury and regeneration' model for prostate carcinogenesis, injury caused by pathogens or pro-inflammatory cytotoxic agents would trigger proliferation of prostatic glandular cells, leading to the appearance of epithelial lesions named 'Proliferative Inflammatory Atrophy' (PIA). Inflammatory cells infiltrating the prostate would release genotoxic reactive oxygen species, leading atrophic cells to neoplastic progression. The hypothesis pointing to PIA as risk-lesion for prostate cancer has been extensively investigated at the cellular and molecular levels, but few morphological data are available linking PIA or prostatic intraepithelial neoplasia (PIN) to inflammation or clinical prostatitis. We investigated at the morphological level 1367 prostate biopsies from 98 patients with a recent history of chronic prostatitis, and 32 patients with biopsies positive for carcinoma. Our results show that i) PIA is found more frequently in biopsy cores containing a severe or moderate inflammatory focus, compared to NON-PIA lesions (partial or cystic atrophy); ii) the PIA lesion post-atrophic hyperplasia is more frequently found in tissues showing mild or no inflammation; iii) the extent of PIA per patient correlates with the burden of moderate or severe inflammation, whereas NON-PIA lesions do not; iv) low-grade PIN is in over 90% of cases emerging from normal, non-atrophic glands and is more frequently found in biopsy cores with absent or mild inflammatory burden; v) the inverse relationship between the prevalence of low-grade PIN and the extent of PIA lesions per patient is described by a power law function, suggesting the low likelihood of the concomitant presence of these lesions in the same tissue; vi) NON-PIA lesions correlate inversely with neoplasia in patients with prostate cancer; vii) the total scores of the NIH-CPSI questionnaire correlate with both PIA and inflammation burdens at diagnosis of prostatitis but not after pharmacological intervention. These results point to a positive association between tissue inflammation, clinical prostatitis and the putative cancer risk-lesion PIA, but do not support a model whereby low-grade PIN would arise from PIA.

Griesser H.,Cytodiagnostics | Skonietzki S.,Center For Gynecology Andreasstr 51 | Fischer T.,Clinical Research | Fielder K.,Clinical Research | Suesskind M.,Dr. Kade Pharmazeutische Fabrik
Maturitas | Year: 2012

Objective: The aim of the study was to confirm the superior efficacy of estriol containing pessaries compared to placebo in the treatment of vaginal atrophy. Study design: In a prospective, multicenter, randomized, placebo-controlled, double-blind study, 436 postmenopausal women with vaginal atrophy (vaginal maturation index, VMI < 40%; vaginal pH > 5; most bothersome symptom, MBS ≥ 65 on visual analogue scale, VAS) were treated with pessaries containing either 0.2 mg estriol (N = 142) or 0.03 mg estriol (N = 147) or with a matching placebo (N = 147) for 12 weeks. Main outcome measures: Primary efficacy endpoints included increase in VMI, decrease of the vaginal pH value and decrease in intensity of MBS after 12 weeks of treatment. Results: The increase in VMI was significantly greater under 0.2 mg estriol and 0.03 mg estriol (46.3 ± 17.0 and 38.4 ± 19.4, respectively) compared to placebo (23.9 ± 21.5; p values < 0.001), vaginal pH decreased significantly more (-1.6 ± 0.8 and -1.4 ± 0.9, respectively) compared to placebo (-0.6 ± 0.8; p values < 0.001) and MBS intensity (VAS) declined significantly more (-52.2 ± 23.7 and -47.1 ± 23.4, respectively) compared to placebo (-31.8 ± 26.3; p values < 0.001). Adverse events were rare and occurred at similar rates in all three groups. Conclusions: Superiority of estriol containing pessaries over placebo was shown in the local treatment of vaginal atrophy. Even a very low dose of 0.03 mg estriol proved sufficient for local treatment of vaginal atrophy with excellent tolerability. © 2012 Elsevier Ireland Ltd. All rights reserved.

Pacheco B.,University of Toronto | Pacheco B.,Cytodiagnostics | Crombet L.,University of Toronto | Loppnau P.,University of Toronto | Cossar D.,University of Toronto
Protein Expression and Purification | Year: 2012

Heterologous protein expression in Escherichia coli is commonly used to obtain recombinant proteins for a variety of downstream applications. However, many proteins are not, or are only poorly, expressed in soluble form. High level expression often leads to the formation of inclusion bodies and an inactive product that needs to be refolded. By screening the solubility pattern for a set of 71 target proteins in different host-strains and varying parameters such as location of purification tag, promoter and induction temperature we propose a protocol with a success rate of 77% of clones returning a soluble protein. This protocol is particularly suitable for high-throughput screening with the goal to obtain soluble protein product for e.g. structure determination. © 2011 Elsevier Inc. All rights reserved.

Ziemke P.,Institute of Pathology | Marquardt K.,Pathology Laboratory | Griesser H.,Cytodiagnostics
Acta Cytologica | Year: 2014

Objective: The reliability of cytological diagnoses, especially for low-grade squamous intraepithelial lesions (LSIL), is limited. This leads to uncertainty in patient management. The application of adjunctive biomarkers is meant to improve this situation. Therefore, we examined the prognostic value of p16/Ki-67 immunostaining of LSIL cytology specimens. Study Design: We analyzed the p16INK4a and Ki-67 immunocytochemistry (CINtec® PLUS, dual stain) of 260 patients with LSIL. Cytology and dual-stain results were correlated with histology at the time of treatment or with cytological follow-up. Results: After an average duration of 24.9 months (1-58) and a histology rate of 36.2% [cervical intraepithelial neoplasia, grade 2 or higher (CIN2+) as positive], the statistical evaluation for cytology and dual stain resulted in a sensitivity of 98.3 and 90.0%, respectively, a specificity of 74.5% for dual stain, a positive predictive value (PPV) of 22.8 and 51.4%, and a negative predictive value (NPV) of 96.1% for dual stain. Conclusion: The combined immunocytochemical investigation of p16INK4a and Ki-67 leads to a significantly better PPV and a very good NPV for CIN2+ in LSIL, especially in women 30 years of age and older. An objective individualized prognosis may not be achieved with p16INK4a/Ki-67. Statistical data from our study, however, indicate that patient management can be significantly improved by the application of combined p16/Ki-67 immunocytochemistry as an adjunct to cytology. © 2014 S. Karger AG, Basel.

Loading Cytodiagnostics collaborators
Loading Cytodiagnostics collaborators